Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Short-term Investments (2009 - 2025)

Grifols' (GIFLF) quarterly Short-term Investments came in at $201.4 million in Q4 2025, down 20.82% on a YoY basis from $254.3 million in Q4 2024, and down 20.82% quarter-over-quarter from $254.3 million in Q4 2024.

Analysis

Grifols (GIFLF) Short-term Investments (2009 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Short-term Investments for 17 consecutive years, with $201.4 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments fell 20.82% year-over-year to $201.4 million; the trailing twelve-month figure through Dec 2025 stood at $201.4 million (down 20.82% YoY), and the FY2025 full-year result was $195.5 million, down 23.15% from the prior year.
  • Short-term Investments declined to $201.4 million in Q4 2025 per GIFLF's latest filing, from $254.3 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $2.3 billion in Q4 2021 and bottomed at -$100.1 million in Q4 2023.
  • Historically, Short-term Investments has averaged $628.2 million across 5 years, with a median of $254.3 million in 2024.
  • The sharpest annual moves came in 2021 and 2023: Short-term Investments surged 7238.35% in 2021, then sank 121.41% in 2023.
  • Over 5 years, Short-term Investments stood at $2.3 billion in 2021, then slumped by 79.84% to $467.3 million in 2022, then tumbled by 121.41% to -$100.1 million in 2023, then soared by 354.17% to $254.3 million in 2024, then dropped by 20.82% to $201.4 million in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods registered $201.4 million, $254.3 million, and -$100.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 201.38 Mn
Dec 31, 2024 254.33 Mn
Dec 31, 2023 -100.06 Mn
Dec 31, 2022 467.32 Mn
Dec 31, 2021 2.32 Bn
Dec 31, 2020 -32.48 Mn
Sep 30, 2020 14.35 Mn
Mar 31, 2020 14.39 Mn
Dec 31, 2019 -21.53 Mn
Sep 30, 2019 3.08 Mn
Mar 31, 2019 202.58 Mn
Dec 31, 2018 122.81 Mn
Sep 30, 2018 59.78 Mn
Jun 30, 2018 45.28 Mn
Mar 31, 2018 12.92 Mn
Dec 31, 2017 12.64 Mn
Jun 30, 2017 22.56 Mn
Dec 31, 2016 2.79 Mn
Sep 30, 2016 1.99 Mn
Jun 30, 2016 9.07 Mn